• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by BioXcel Therapeutics Inc.

    4/4/25 4:16:14 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTAI alert in real time by email
    S-8 1 tm2511409d1_s8.htm FORM S-8

     

     

    As filed with the Securities and Exchange Commission on April 4, 2025

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    BioXcel Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   82-1386754

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    555 Long Wharf Drive

    New Haven, CT 06511

    (Address of Principal Executive Offices) (Zip Code)

     

    BioXcel Therapeutics, Inc. 2020 Incentive Award Plan

    BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan

    (Full title of the plans)

     

    Vimal Mehta, Ph.D.
    Chief Executive Officer
    BioXcel Therapeutics, Inc.
    555 Long Wharf Drive
    New Haven, CT 06511
    (Name and address of agent for service)

     

    (475) 238-6837

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    N. Danny Shulman

    Emily Johns

    Honigman LLP

    1440 New York Avenue, NW Suite 200

    Washington, DC 20005

    (202) 844 3380

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
    Non-accelerated filer x   Smaller reporting company x
          Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

     

    This Registration Statement on Form S-8 is being filed with the U.S. Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 155,120 shares of common stock, par value $0.001 per share (the “Common Stock”), of BioXcel Therapeutics, Inc. (the “Company”), issuable under the following employee benefit plans for which a registration statement of the Company on Form S-8 (File Nos. 333-238580, 333-266922, 333-270652 and 333-278492) is effective: (i) the BioXcel Therapeutics, Inc. 2020 Incentive Award Plan (the “2020 Plan”) and (ii) the BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the “2020 ESPP”). Pursuant to General Instruction E of Form S-8, the contents of the above-referenced prior registration statements are incorporated into this Registration Statement by reference herein.

     

    INCORPORATION BY REFERENCE

     

    The following documents filed with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:

     

    • Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 28, 2025.

     

    • Our Current Reports on Form 8-K, filed with the SEC on January 8, 2025, January 16, 2025, January 29, 2025, February 6, 2025, March 3, 2025, March 4, 2025, March 21, 2025 and March 21, 2025.

     

    • The description of our common stock contained in our Registration Statement on Form 8-A, filed with the SEC on March 5, 2018, as updated by “Description of the Registrant’s Securities Registered under Section 12 of the Exchange Act” filed as Exhibit 4.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and any amendment or report filed with the SEC for the purpose of updating such description.

     

    In addition, all reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the “Exchange Act” in this prospectus, prior to the termination of this offering, including all such documents we may file with the SEC after the date of filing of this registration statement and prior to the effectiveness of this registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents.

     

    Any statement herein or contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.

     

     

     

     

    Item 8. EXHIBITS.

     

    Exhibit           Incorporated by
    Reference
           
    Number   Exhibit Description   Form   File
    Number
      Filing
    Date
      Exhibit   Filed
    Herewith
                   
      3.1   Amended and Restated Certificate of Incorporation   10-Q   001-38410   8-10-2021   3.1    
                   
      3.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation   8-K   001-38410   6-12-2024   3.1    
                   
      3.3   Certificate of Amendment to the Amended and Restated Certificate of Incorporation   8-K   001-38410   2-6-2025   3.1    
                               
      3.4   Amended and Restated Bylaws   8-K   001-38410   3-13-2018   3.2    
                   
      3.5   Specimen Stock Certificate evidencing the shares of common stock.   S-1/A   333-22990   2-26-2018   4.2    
                               
      5.1   Opinion of Honigman LLP                   *
                               
      23.1   Consent of Ernst & Young LLP, independent registered public accounting firm                   *
                               
      23.2   Consent of Honigman LLP (included in Exhibit 5.1)                   *
                   
      24.1   Power of Attorney (included on the signature page of the Registration Statement)                   *
                   
      99.1   BioXcel Therapeutics, Inc. 2020 Incentive Award Plan   10-Q   001-38410   8-14-2020   10.1    
                   
      99.2   BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan   10-Q   001-38410   8-14-2020   10.2    
                               
      107.1   Filing Fee Table                   *

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New Haven, State of Connecticut, on this 4th day of April, 2025.

     

    BioXcel Therapeutics, Inc.  
         
    By  /s/ Vimal Mehta  
      Vimal Mehta  
      Chief Executive Officer, President and Director  

     

    POWER OF ATTORNEY

     

    Each of the undersigned officers and directors of the registrant hereby severally constitutes and appoints Vimal Mehta, Ph.D. and Richard Steinhart, and each of them singly (with full power to each of them to act alone), as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution in each of them, for him or her and in his or her name, place and stead, and in any and all capacities, to file and sign any and all amendments, including post-effective amendments, to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Vimal Mehta, Ph.D.   Chief Executive Officer, President and Director    April 4, 2025
    Vimal Mehta, Ph.D.   (principal executive officer)    
             
    /s/ Richard Steinhart   Chief Financial Officer    April 4, 2025
    Richard Steinhart   (principal financial officer and principal accounting officer)    
             
    /s/ Peter Mueller, Ph.D.   Chairman of the Board of Directors    April 4, 2025
    Peter Mueller, Ph.D.        
             
    /s/ June Bray   Director    April 4, 2025
    June Bray        
             
    /s/ Sandeep Laumas, M.D.   Director    April 4, 2025
    Sandeep Laumas, M.D.        
             
    /s/ Michael Miller   Director    April 4, 2025
    Michael Miller        
             
    /s/ Michal Votruba, M.D., Ph.D.   Director    April 4, 2025
    Michal Votruba, M.D., Ph.D.        

     

    /s/ David Mack   Director    April 4, 2025
    David Mack        

     

    /s/ Rajiv Patni, M.D.   Director    April 4, 2025
    Rajiv Patni, M.D.        

     

     

     

    Get the next $BTAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTAI

    DatePrice TargetRatingAnalyst
    2/21/2024$9.00 → $4.00Buy → Neutral
    UBS
    8/15/2023$40.00 → $4.00Buy → Neutral
    Mizuho
    7/17/2023Buy → Neutral
    Guggenheim
    3/10/2023$20.00 → $22.00Buy → Hold
    Jefferies
    12/1/2022$16.00Sell → Neutral
    Goldman
    7/7/2022$19.00Buy
    Mizuho
    4/6/2022$80.00Buy
    BofA Securities
    2/16/2022$88.00 → $25.00Buy
    UBS
    More analyst ratings

    $BTAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Laumas Sandeep

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    1/12/26 7:09:53 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Patni Rajiv

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    1/12/26 7:08:04 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mueller Peter

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    1/12/26 7:06:49 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting

    sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI® Submission timeline supports potential approval of IGALMI® label expansion as early as year-end 2026 NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home

    1/20/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

    NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced that it plans to submit a supplemental New Drug Application (sNDA) this month seeking the U.S. Food and Drug Administration's (FDA) approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia. "We are pleased with the progress towards submission of the sNDA and launch planning," said Vimal Mehta, Ph.D., Chief Executive Officer of BioXcel Therapeutics. "Based on the accelerated submission timeline, we

    1/7/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by BioXcel Therapeutics Inc.

    SCHEDULE 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    2/9/26 4:13:17 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    2/6/26 5:00:36 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    1/20/26 7:00:40 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioXcel Therapeutics downgraded by UBS with a new price target

    UBS downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $9.00 previously

    2/21/24 8:16:51 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics downgraded by Mizuho with a new price target

    Mizuho downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $40.00 previously

    8/15/23 7:17:23 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics downgraded by Guggenheim

    Guggenheim downgraded BioXcel Therapeutics from Buy to Neutral

    7/17/23 7:16:08 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Leadership Updates

    Live Leadership Updates

    View All

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

    Vincent J. O'Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer   Rajiv Patni, M.D., appointed Strategic Clinical Advisor to CEO and Board of Directors NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company's strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates. Vincent J. O'Neill, M.D., Senior Vice

    12/11/23 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

    NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Michael P. Miller to its Board of Directors, effective July 1, 2022. Mr. Miller brings nearly 40 years of strategic leadership and commercial growth experience in the pharmaceutical industry, where he most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals. "We are pleased to welcome Mike to our Board and believe his deep commercial and market access expertise will be

    7/5/22 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Financials

    Live finance-specific insights

    View All

    UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

    BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of BXCL501 in the outpatient setting without the supervision of a healthcare provider More than 2400 episodes of agitation were treated in the SERENITY At-Home

    8/27/25 8:00:16 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

    BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of BXCL501 in the outpatient setting without the supervision of a healthcare provider More than 2400 episodes of agitation were treated in the SERENITY

    8/27/25 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

    Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2

    3/27/25 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioXcel Therapeutics Inc.

    SC 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    9/10/24 10:47:52 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by BioXcel Therapeutics Inc. (Amendment)

    SC 13D/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    6/6/24 8:29:42 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by BioXcel Therapeutics Inc. (Amendment)

    SC 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    2/9/24 8:35:57 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care